Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature
- 9 February 2010
- journal article
- case report
- Published by Springer Nature in Clinical Rheumatology
- Vol. 29 (5) , 563-566
Abstract
Antitumor necrosis factor (TNF) therapy has been associated with adverse immunologic events including systemic lupus erythematosus. However, the development of polymyositis (PM)/dermatomyositis (DM) associated with anti-TNF therapy is extremely rare. We experienced a case of a 48-year-old female with rheumatoid arthritis (RA) who had anti-Jo-1 antibodies and interstitial lung disease but no previous history of PM/DM and who developed PM soon after the initiation of etanercept (ETN) therapy for RA. The patient recovered upon withdrawal from ETN and corticosteroid (CS) therapies. Only four reports of PM/DM associated with anti-TNF therapy for RA could be found in the literature. The patients described in three of the four reports were positive for anti-Jo-1 antibodies before the initiation of anti-TNF therapy, and in all the cases, recovery occurred after the cessation of anti-TNF-agent administration and CS therapy. These results suggest a relationship between the onset of PM/DM with anti-Jo-1 antibody and anti-TNF therapy for RA.Keywords
This publication has 17 references indexed in Scilit:
- A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathiesAnnals of the Rheumatic Diseases, 2008
- Open-Label Trial of Anti-TNF-α in Dermato- and Polymyositis Treated Concomitantly with MethotrexateEuropean Neurology, 2008
- Polymyositis associated with infliximab treatment for rheumatoid arthritisModern Rheumatology, 2006
- Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitorArthritis Care & Research, 2006
- Cytokines in idiopathic inflammatory myopathiesAutoimmunity, 2006
- Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximabRheumatology, 2004
- Refractory polymyositis responding to infliximabRheumatology, 2004
- Efficacy and safety of the anti-TNF biologic agentsModern Rheumatology, 2004
- Refractory polymyositis responding to infliximab: extended follow-upRheumatology, 2004
- Polymyositis associated with infliximab treatment for rheumatoid arthritisRheumatology, 2003